Safety data from the phase III Japanese ACHIEVE trial: Part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer

Masahito Kotaka, Takeharu Yamanaka, Takayuki Yoshino, Dai Manaka, Tetsuya Eto, Junichi Hasegawa, Akinori Takagane, Masato Nakamura, Takeshi Kato, Yoshinori Munemoto, Fumitaka Nakamura, Hiroyuki Bando, Hiroki Taniguchi, Makio Gamoh, Manabu Shiozawa, Shigetoyo Saji, Yoshihiko Maehara, Tsunekazu Mizushima, Atsushi Ohtsu, Masaki Mori

研究成果: Contribution to journalArticle

9 引用 (Scopus)

抜粋

Background The International Duration Evaluation of Adjuvant chemotherapy project investigated whether a shorter duration of oxaliplatin-based adjuvant chemotherapy was as effective as 6 months of identical chemotherapy for resected stage III colon cancer. As part of this project, we report safety data from the Japanese ACHIEVE study (JFMC47-1202-C3). Patients and methods ACHIEVE was an open-label, multicentre trial randomising patients with stage III colon cancer to receive 3 m or 6 m of mFOLFOX6/CAPOX after surgery. Choice of regimen was declared before randomisation by a site investigator. Results Between August 2012 and June 2014, 1313 patients were enrolled and, of those, 1277 were analysed for the safety analysis, with 635 in arm 6 (mFOLFOX6, n=158; CAPOX, n=477) and 642 in arm 3 (mFOLFOX6, n=161; CAPOX, n=481). Grade 3 or worse peripheral sensory neuropathy (PSN) developed in 5%/0.6% of patients receiving mFOLFOX6 in arm 6/3 (p=0.019) and 6%/1% of those receiving CAPOX in arm 6/3 (p<0.001). Similarly, grade 2 or worse PSN developed in 36%/11% of patients receiving mFOLFOX6 in arm 6/3 (p<0.001) and 37%/14% of those receiving CAPOX in arm 6/3 (p<0.001). An association between baseline creatinine clearance (CCr) and adverse events (AEs) was found that patients with CAPOX were significantly more likely to develop AEs ≥grade 3 when they had a CCr ≤50 (OR 1.67; p=0.048). Conclusions We confirmed in the Japanese population that the shorter duration of adjuvant chemotherapy resulted in a significant reduction of PSN. In patients with CAPOX, renal function was significantly related to severe AEs. Trial registration number UMIN000008543, Results.

元の言語英語
記事番号e000354
ジャーナルESMO Open
3
発行部数3
DOI
出版物ステータス出版済み - 4 1 2018

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

フィンガープリント Safety data from the phase III Japanese ACHIEVE trial: Part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Kotaka, M., Yamanaka, T., Yoshino, T., Manaka, D., Eto, T., Hasegawa, J., Takagane, A., Nakamura, M., Kato, T., Munemoto, Y., Nakamura, F., Bando, H., Taniguchi, H., Gamoh, M., Shiozawa, M., Saji, S., Maehara, Y., Mizushima, T., Ohtsu, A., & Mori, M. (2018). Safety data from the phase III Japanese ACHIEVE trial: Part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer. ESMO Open, 3(3), [e000354]. https://doi.org/10.1136/esmoopen-2018-000354